[
ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26, 345–348, 2000.10.1038/8166411062477
]Search in Google Scholar
[
Campion J, Maricic M. Osteoporosis in men. Am Fam Physician 67, 1521–1526, 2003.
]Search in Google Scholar
[
Carpenter T. Oncogenic osteomalacia--a complex dance of factors. N Engl J Med 348, 1705–1708, 2003.10.1056/NEJMe03003712711747
]Search in Google Scholar
[
Chong W, Molinolo A, Chen C, Collins M. Tumor-induced osteomalacia. Endocr Relat Cancer 18, R53–77, 2011.10.1530/ERC-11-0006343374121490240
]Search in Google Scholar
[
Clifton-Bligh R, Hofman M, Duncan E, Sim Ie, Darnell D, Clarkson A, Wong T, Walsh J, Gill A, Ebeling P, Hicks R. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab 98, 687–694, 2013.10.1210/jc.2012-364223295468
]Search in Google Scholar
[
Colt E, Gopan T, Chong H. Oncogenic osteomalacia cured by removal of an organized hematoma. Endocrine Practice 11, 190–193, 2005.10.4158/EP.11.3.19016239206
]Search in Google Scholar
[
Econs M, Drezner M. Tumor-induced osteomalacia--unveiling a new hormone. N Engl J Med 330, 1679–1681, 1994.10.1056/NEJM1994060933023108177274
]Search in Google Scholar
[
Edmister K, Sundaram M. Oncogenic osteomalacia. Semin Musculoskelet Radiol 6, 191–196, 2002.10.1055/s-2002-3671612541196
]Search in Google Scholar
[
El-Maouche D, Sadowski S, Papadakis G, Guthrie L, Cottle-Delisle C, Merkel R, Millo C, Chen C, Kebebew E, Collins MT. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101, 3575–3581, 2016.10.1210/jc.2016-2052505234427533306
]Search in Google Scholar
[
Hautmann A, Hautmann M, Kolbl O, Herr W, Fleck M. Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 17, 512, 2015.10.1007/s11926-015-0512-525900190
]Search in Google Scholar
[
Hu F, Jiang C, Zhang Q, Shi H, Wei L, Wang Y. Quantitative ELISA-like immunohistochemistry of fibroblast growth factor 23 in diagnosis of tumor-induced osteomalacia and clinical characteristics of the disease. Dis Markers 2016, 3176978, 2016.10.1155/2016/3176978480852827034530
]Search in Google Scholar
[
Jagtap V, Sarathi V, Lila A, Malhotra G, Sankhe S, Bandgar T, Menon P, Shah N. Tumor-induced osteomalacia: a single center experience. Endocrine Practice 17, 177–184, 2011.10.4158/EP10151.OR
]Search in Google Scholar
[
Jan de Beur SM. Tumor-induced osteomalacia. JAMA 294, 1260–1267, 2005.10.1001/jama.294.10.1260
]Search in Google Scholar
[
Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y, Jamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang M, Miyauchi A, Econs M, Lavinge J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348, 1656–1663, 2003.10.1056/NEJMoa020881
]Search in Google Scholar
[
Liu S, Zhou X, Song A, Huo Z, Wang Y, Xia W, Liu Y. Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot. Medicine (Baltimore) 98, e16296, 2019.10.1097/MD.0000000000016296
]Search in Google Scholar
[
Perwad F, Zhang M, Tenenhouse H, Portale A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293, F1577–F1583, 2007.10.1152/ajprenal.00463.2006
]Search in Google Scholar
[
Ryan E, Reiss E. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 77, 501–512, 1984.10.1016/0002-9343(84)90112-8
]Search in Google Scholar
[
Seemann L, Padala S, Mohammed A, Belayneh N. Tumor-induced osteomalacia and the importance of plasma fibro-blast growth factor 23 as an indicator: diagnostic delay leads to a suicide attempt. J Investig Med High Impact Case Rep 7, 2324709619895162, 2019.10.1177/2324709619895162692352631850815
]Search in Google Scholar
[
Siegel H, Rock M, Inwards C, Sim F. Phosphaturic mesenchymal tumor. Orthopedics 25, 1279–1281, 2002.10.3928/0147-7447-20021101-2112452347
]Search in Google Scholar
[
Slot-Steenks M, Hamdy N, van de Sande M, Vriens D, Cleven A, Appelman-Dijkstra N. Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. Endocrine 54, 642–647, 2016.10.1007/s12020-016-1092-5510720127709474
]Search in Google Scholar
[
The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11, 130–136, 1995.10.1038/ng1095-1307550339
]Search in Google Scholar
[
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 30, 473–483, 1992.10.1097/00005650-199206000-00002
]Search in Google Scholar
[
Wu W, Wang C, Ruan J, Chen F, Li N, Chen F. A case report of phosphaturic mesenchymal tumor-induced osteomalacia. Medicine (Baltimore) 96, e9470. 2017.10.1097/MD.0000000000009470575828829390586
]Search in Google Scholar
[
Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87, 4957–4960, 2002.10.1210/jc.2002-02110512414858
]Search in Google Scholar
[
Yu W, He J, Fu W, Wang C, Zhang Z. Reports of 17 Chinese patients with tumor-induced osteomalacia. J Bone Miner Metab 35, 298–307, 2017.10.1007/s00774-016-0756-927085966
]Search in Google Scholar
